CURE Pharmaceutical has developed innovative drug delivery technology in CureFilm, an oral film strip that dissolves in the mouth, allows for multiple active ingredients in one dosage, and features higher bioavailability.

In recent years the pharmaceutical industry has seen a significant change to the way its manufacturersand supply chains operate, due to the establishment of several serialization and track and trace regulations mandated globally.

Patient-centricity has become an important focus for drug developers and an essential element of clinical studies aimed at showing that a new therapy addresses real patient needs. How companies define patient-centric trials sometimes differ.

Clinical trials are evolving away from trials based solely at investigator sites, moving on to the patient’s home, requiring direct-to-patient services in order for patients to participate.

Life Science companies, both large and small, are seeking more strategic partnerships with vendors.

Worldwide, around 47 million people have dementia, and there are 9.9 million new cases every year, according to recent data from the World Health Organization (WHO)1.Alzheimer's disease (AD) is the most common cause of dementia and may contribute to 60–70% of cases.

1. What makes the market demand rising for integrated delivery system?
The market demand for integrated delivery systems which combine an injectable drug, its container and the system used to administer it—continues to grow due, in large part, to the popularity of self-administered therapies for rheumatoid arthritis, diabetes and other chronic conditions.

A method of testing drugs thatprompt the immune system to attack and destroy cancer cells has been developed which can speed up drug discovering andreducethe unnecessary use of mice in drug screening programmes.

Orphan genetic diseases have become an increasingly popular area for drug development through a variety of novel mechanistictherapeutic approaches.

1.Quanticate has just completed an investment initiative to upgrade its pharmacovigilance safety data base,how will the new system simplify event reporting in the EU and enhance data availability to stake holders?

1. In an environment where trial data is made available through peer reviewed articles how effective is clinical trial disclosure maturity assessment with increased risk, complexity and costs to assess global disclosure processes?

What are the current problems or challenges faced in clinical trial payments process?
There are countless challenges around clinical trial payments, but they can be best categorized into two core themes – the increasing administrative burdens around processing and reconciling payments as well as the lack of transparency and visibility into financial transactions.

The market demand for integrated delivery systems which combine an injectable drug, its container and the system used to administer it continues to grow due, in large part, to the popularity of self-administered therapies for rheumatoid arthritis, diabetes and other chronic conditions.

Contributors

  • Sample avatar

    Arthur Smith

    Global Marketing Manager Videojet Technologies

  • Sample avatar

    Barbara Zupancic

    Director Patient Recruitment and Retention Worldwide Clinical Trials

  • Sample avatar

    Scott Gray

    CEO Clincierge

  • Sample avatar

    GRAHAM REYNOLDS

    VICE PRESIDENT GENERAL MANAGER GLOBAL BIOLOGICS WEST PHARMACEUTICAL SERVICES

  • Sample avatar

    Ariette van Strien

    Chief Commercial Officer Marken

  • Sample avatar

    Chitra Lele

    Chief Scientific Officer Sciformix Corporation

Sign up via our free email subscription service to receive notifications when new information is available.
captcha